|
Originally published In Press as doi:10.1074/jbc.M203466200 on July 16, 2002
J. Biol. Chem., Vol. 277, Issue 37, 34642-34650, September 13, 2002
Association of Helicobacter pylori Vacuolating Toxin
(VacA) with Lipid Rafts*
Wayne
Schraw §,
Yi
Li §¶,
Mark S.
McClain ,
F. Gisou
van der Goot , and
Timothy L.
Cover ¶**
From the Departments of Medicine and
¶ Microbiology and Immunology, Vanderbilt University School of
Medicine and ** Veterans Affairs Medical Center,
Nashville, Tennessee 37232 and the Department of Genetics and
Microbiology, University of Geneva, CH-1211 Geneva 4, Switzerland
Received for publication, April 10, 2002, and in revised form, July 12, 2002
 |
ABSTRACT |
A variety of extracellular ligands and pathogens
interact with raft domains in the plasma membrane of eukaryotic cells.
In this study, we examined the role of lipid rafts and raft-associated glycosylphosphatidylinositol (GPI)-anchored proteins in the process by
which Helicobacter pylori vacuolating toxin (VacA)
intoxicates cells. We first investigated whether GPI-anchored proteins
are required for VacA toxicity by analyzing wild-type Chinese hamster ovary (CHO) cells and CHO-LA1 mutant cells that are defective in
production of GPI-anchored proteins. Whereas wild-type and mutant cells
differed markedly in susceptibility to aerolysin (a bacterial toxin
that binds to GPI-anchored proteins), they were equally susceptible to
VacA. We next determined whether VacA physically associates with lipid
rafts. CHO or HeLa cells were incubated with VacA, and
Triton-insoluble membranes then were separated by
sucrose density gradient centrifugation. Immunoblot analysis revealed that a substantial proportion of
cell-associated toxin was associated with detergent-resistant membranes
(DRMs). DRM association required acid activation of the purified toxin prior to contact with cells, and acid activation also was required for
VacA cytotoxicity. Treatment of cells with methyl- -cyclodextrin (a
cholesterol-depleting agent) did not inhibit VacA-induced
depolarization of the plasma membrane, but interfered with the
internalization or intracellular localization of VacA and inhibited the
capacity of the toxin to induce cell vacuolation. Treatment of cells
with nystatin also inhibited VacA-induced cell vacuolation. These data indicate that VacA associates with lipid raft microdomains in the
absence of GPI-anchored proteins and suggest that association of the
toxin with lipid rafts is important for VacA cytotoxicity.
 |
INTRODUCTION |
Helicobacter pylori are Gram-negative bacteria that
colonize the human gastric mucosa. Infection with these organisms
consistently results in gastric inflammation and is a risk factor for
the development of peptic ulcer disease, distal gastric adenocarcinoma,
and gastric lymphoma (1, 2). Many H. pylori strains secrete
a toxin (VacA) that exerts a variety of effects on
epithelial cells in vitro, including the
formation of large intracellular vacuoles, formation of
anion-selective pores in the plasma membrane, apoptosis, and epithelial
monolayer permeabilization (3-5).
Several studies in animal models have suggested that VacA is an
important virulence factor produced by H. pylori. In a mouse model, a VacA-producing strain exhibited an enhanced capacity to
colonize the stomach compared with an isogenic vacA-mutant strain, particularly in co-infection experiments (6). Studies in mouse
and gerbil models also have suggested that VacA contributes to gastric
mucosal injury (7, 8). Analyses of H. pylori isolates from
humans have revealed that strains isolated from patients with peptic
ulcer disease typically produce VacA proteins with detectable cytotoxic
activity in vitro (encoded by vacA alleles belonging to the type s1 family), whereas strains isolated from patients with no history of peptic ulcer disease commonly produce VacA
proteins that lack detectable cytotoxic activity in vitro (encoded by vacA alleles belonging to the type s2 family)
(9-14).
The vacA gene encodes a 140-kDa protoxin, which undergoes
cleavage of an amino-terminal signal sequence and cleavage of a carboxyl-terminal peptide to yield an 88 kDa secreted toxin (3-5,15). Secretion of VacA occurs via an autotransporter mechanism (16). When
isolated in a purified form from broth culture supernatant, VacA is in
an oligomeric state consisting predominantly of dodecameric or
tetradecameric flower-shaped structures (17-19). These oligomeric forms of VacA are relatively inactive when added to eukaryotic cells
in vitro (18, 20, 21). However, exposure of purified VacA to
acidic or alkaline pH conditions results in disassembly of VacA
oligomers into monomeric subunits and is associated with a marked
increase in its cytotoxicity (18, 20-22). Thus, it is presumed that
VacA toxicity requires binding of monomeric forms of the toxin to the
plasma membrane.
Following binding of VacA to the surface of eukaryotic cells, the toxin
can insert into the plasma membrane to form anion-selective channels
(23-26) and can also be internalized (20, 27, 28). Intracellular
expression of VacA by transient tranfection with VacA-encoding plasmids
results in the formation of intracellular vacuoles that are
indistinguishable from those that form when VacA is added to the
outside of cells (29, 30), suggesting that this toxin acts
intracellularly. HEp-2 cells expressing dominant negative mutants of
two proteins required for clathrin-dependent endocytosis
(Eps 15 and dynamin II) develop cellular vacuoles in response to VacA
(31), which suggests that VacA internalization can occur via a
clathrin-independent endocytic pathway. It has been proposed that VacA
toxicity requires localization of the toxin in either endosomes or
mitochondria (28, 32). One current model for understanding the
cytotoxic effects of VacA proposes that its cell-vacuolating activity
results from the formation of anion-selective channels in endosomal
membranes (5, 23-26). Alternatively, it is possible that VacA might
have novel intracellular activities distinct from membrane channel
formation (5, 33, 34). In summary, there continues to be considerable
uncertainty about the site of VacA action and the molecular mechanisms
underlying its toxic activity.
In recent years, it has been recognized that a variety of pathogens and
toxins interact with microdomains in the plasma membrane known as lipid
rafts (35). Lipid rafts are membrane microdomains that are enriched in
cholesterol, sphingolipids, and glycosylphosphatidylinositol (GPI)1-anchored proteins
(36-39). Several bacterial, viral, and parasitic pathogens seem to use
rafts as a site for gaining entry into mammalian cells (40, 41). In
addition, certain bacterial toxins, including aerolysin, perfringolysin
O, cholera toxin, and tetanus toxin, utilize rafts as either a site for
high affinity binding and oligomerization on the surface of cells or as
a site for internalization into host cells (42-46). A recent study
reported that treatment of HEp-2 cells with
phosphatidylinositol-specific phospholipase C (PI-PLC), an agent that
removes GPI-anchored proteins from the cell surface, inhibited the
capacity of VacA to induce cell vacuolation (31). It also was reported
that incubation of the cells with nystatin (a cholesterol-binding
agent) inhibited VacA-induced cell vacuolation (31). Based on these
results, it was proposed that the presence of one or more GPI-anchored
proteins and intact membrane lipid rafts are required for VacA
cytotoxicity. Specifically, it was hypothesized that VacA monomers
might bind to GPI-anchored proteins and that lipid rafts might act as
concentrating platforms enabling VacA to concentrate locally and
oligomerize efficiently (31). However, there has not yet been any
direct evidence indicating that VacA physically interacts with either
GPI-anchored proteins or lipid rafts. In the current study, we provide
biochemical evidence indicating that VacA associates with lipid raft
microdomains and report that the presence of GPI-anchored proteins is
not required for either association of the toxin with rafts or
VacA-induced cell vacuolation. In addition, we present data suggesting
that VacA interaction with lipid rafts is an important feature of the process by which VacA intoxicates cells.
 |
MATERIALS AND METHODS |
Purification of H. pylori VacA and Aeromonas
Proaerolysin--
VacA was purified in an oligomeric form from culture
supernatant of H. pylori strain 60190, as described
previously (18, 20, 23). In most experiments, purified VacA was
acid-activated by the slow addition of 200 mM HCl to the
toxin preparation until a pH of 3 was reached (20, 21). Proaerolysin
was purified from culture supernatant of Aeromonas
salmonicida as described previously (47).
Cell Culture Methods--
HeLa cells were grown in Eagle's
medium containing 10% fetal bovine serum, and CHO cells were grown in
Ham's F-12 medium containing 10% fetal bovine serum. Mutant CHO-LA1
cells (defective in production of GPI-anchored proteins) and mutant
cells recomplemented with the PIG-L gene
(i.e. with restored capacity for production of GPI-anchored
proteins, hereafter designated as wild-type CHO cells) have been
described previously (48). In assays to test VacA-induced vacuolation
of cells, the tissue culture medium was supplemented with 5 mM ammonium chloride (49, 50), and VacA was acid-activated as described above. Acid-activated VacA then was diluted in neutral pH
tissue culture medium and was added directly to the neutral pH medium
overlying cells.
Preparation of a VacA Affinity Column--
Purified VacA (~1.2
mg) from H. pylori 60190 (in 25 mM
HEPES buffer, pH 7.2, containing 150 mM sodium chloride)
was incubated with 1 ml of a 1:1 mixture of Affi-Gel 10:Affi-Gel 15 (Bio-Rad) at 4 °C for 4 h, followed by addition of 200 µl of
0.5 M ethanolamine. This preparation then was loaded onto a
2-ml Poly-prep column (Bio-Rad), and the column was sequentially washed
with 10 mM potassium phosphate buffer (pH 7.2) containing
150 mM sodium chloride and 0.02% sodium azide, with 20 mM Tris (pH 8.0) containing 500 mM sodium
chloride, with 100 mM glycine (pH 2.5), with 50 mM Tris (pH 8.8), with 100 mM ammonium
hydroxide (pH 11.5), and finally with 10 mM potassium
phosphate buffer (pH 7.2) containing 150 mM sodium chloride
and 0.02% sodium azide.
Preparation of Affinity-purified anti-VacA Rabbit
Serum--
Anti-VacA rabbit serum 958 (about 1 ml), prepared by
immunizing with purified oligomeric VacA from H. pylori
strain 60190, was passed over CM Affi-Gel Blue (Bio-Rad) to remove
albumin, according to the manufacturer's instructions. The
immunoglobulin fraction was concentrated by precipitation with ammonium
sulfate and resuspended in 10 ml of 10 mM potassium
phosphate buffer (pH 7.2) containing 150 mM sodium chloride
and 0.02% sodium azide. The de-albuminated serum was then applied
three times to the VacA affinity column described above. The column was
washed two times with 5 column volumes of 10 mM potassium
phosphate buffer (pH 7.2) containing 150 mM sodium chloride
and 0.02% sodium azide and then washed two times with 5 column volumes
of 20 mM Tris (pH 8.0) containing 500 mM sodium
chloride. Bound immunoglobulin was eluted with ten 0.5-ml aliquots of
100 mM glycine (pH 2.5) and collected into 100 µl of 1 M Tris (pH 8.0) containing 2.5 mg/ml ovalbumin. Aliquots
were tested for anti-VacA immunoreactivity by immunoblotting, and the
reactive aliquots were pooled. EDTA (10 mM) and sodium
azide (0.02%) were added to the reactive aliquots to facilitate
storage. Residual nonspecific reactivity in the serum was removed by
adsorbing the affinity-purified serum against an Affi-Gel column
(prepared as described above) containing both H. pylori
proteins (from a vacA null mutant strain) and HeLa cell proteins. The purified serum was concentrated to a volume of 2 ml in a
Centricon-30 device, diluted 1:2 with glycerol, and stored at either
4 °C or 20 °C.
Detergent Extraction and Sucrose Density Gradient Centrifugation
of Triton X-100-insoluble Cell Components--
HeLa or CHO cells were
grown to confluence in 75-mm plastic dishes, using Eagle's medium
containing 10% fetal bovine serum or Ham's F-12 medium
containing 10% fetal bovine serum, respectively. Cells were washed
three times with 0.9% NaCl to remove serum, and serum-free Eagle's
containing 1 mg/ml ovalbumin then was added to cells. Approximately
1-2 × 107 cells then were incubated for 1 h at
25 °C with 10 µg/ml H. pylori VacA. Triton-insoluble
cell components were then isolated according to previously published
protocols (51). In brief, cells were washed twice with 0.9% NaCl and
once with Tris-buffered saline (pH 7.4) (TBS) to remove unbound toxin
and then were lysed at 4 °C in 2 ml of TBS (pH 7.4) containing 1%
Triton X-100, 1 mM EDTA, 0.5 mM
phenylmethylsulfonyl fluoride, and a eukaryotic cell protease inhibitor
mixture (Sigma). The lysate was Dounce-homogenized (10 strokes) and
incubated for 30 min on ice. An equal volume of 80% w/v sucrose in TBS
was added to 2 ml of lysate. This was overlayered on a 0.35 ml of 80%
sucrose cushion. The 40% sucrose-containing lysate was successively
overlayered with 4 ml of 30% (w/v) sucrose in TBS and 4.2 ml of 5%
(w/v) sucrose in TBS. Samples were centrifuged for 21 h at
208,000 × g at 4 °C in a Beckman SW 41 TI rotor.
Afterward, 1-ml fractions were collected from the top of the gradient
(fraction 1) to the bottom (fraction 12). Pelleted material recovered
from the bottom of the tube was resuspended in fraction 12. Fractions were stored frozen at 20 °C prior to further analysis.
Analysis of Sucrose Density Gradient Fractions--
Equal
volumes of sucrose density gradient fractions (45 µl) were analyzed
by SDS-PAGE and immunoblotting. Gradient fractions 1 and 2, 9 and 10, and 11 and 12 were routinely pooled (as lanes a,
h, and i, respectively, in Figs. 3-5) to permit
immunoblot analysis of all gradient fractions on a single
polyacrylamide gel. The transferrin receptor was detected in gradient
fractions by using a mouse anti-human transferrin receptor antibody
(Zymed Laboratories Inc.). VacA was detected by using
the affinity-purified rabbit polyclonal anti-VacA antibody preparation
described above. CD55 was detected using rabbit anti-human CD55
affinity-purified antibody (Research Diagnostics Inc.). Immunoblot
analyses were performed using enhanced chemiluminescence (Amersham
Biosciences) with horseradish peroxidase-conjugated secondary
antibodies according to the manufacturer's instructions. Alkaline
phosphatase activity was detected by mixing equal volumes of gradient
fractions with a solution of p-nitrophenyl phosphate (2 mg/ml) in 0.1 M Tris-Cl (pH 9.5), 0.1 M NaCl, 5 mM MgCl2. After incubation at 37 °C for 10 min, the optical density of samples was analyzed at 410 nm. Triplicate
reactions were performed for each gradient fraction.
Immunofluorescence Microscopy--
HeLa or CHO cells were grown
to near confluence on glass coverslips. Cells were incubated for 4 h at 37 °C with purified VacA (either acid-activated or untreated)
in tissue culture medium containing 5 mM ammonium chloride.
The cells then were washed with PBS containing 3% bovine serum albumin
(PBS-BSA), fixed with 3.7% formaldehyde for 5 min, and permeabilized
with 100% methanol for 2 min. The fixed, permeabilized cells were
incubated for 30 min at room temperature with affinity-purified
anti-VacA rabbit serum (diluted 1:5000 in PBS-BSA) and after washing
were incubated for 30 min at room temperature with Cy3-conjugated
anti-rabbit immunoglobulin G (Sigma) diluted 1:250 in PBS-BSA (27).
Alternatively, in some experiments VacA was detected using anti-VacA
monoclonal antibody 5E4 (52), followed by Cy3-conjugated anti-mouse
immunoglobulin G (Sigma). Coverslips were mounted on slides in
Aqua-Polymount (Polysciences), and the cells were visualized with a
Zeiss 410 laser scanning confocal microscope (27).
Depletion of Cellular Cholesterol by
Methyl- -cyclodextrin--
HeLa cells were incubated for 30 min at
37 °C in serum-free Eagle's medium containing 4 mM
methyl- -cyclodextrin (Sigma) prior to addition of VacA. Control
experiments were performed using methyl- -cyclodextrin-cholesterol
complex (27 mg of cholesterol per gram methyl- -cyclodextrin),
prepared as described (53, 54). The cholesterol content of cells was
measured using either thin layer chromatography (48) or an
Infinity cholesterol reagent kit (Sigma).
Analysis of Membrane Potential--
Analyses of membrane
potential were performed as described by Szabo et al. (24),
with several modifications. Briefly, HeLa cells were pretreated with 4 mM methyl- -cyclodextrin at 37 °C for 30 min or left
untreated, washed with 0.9% NaCl, and then detached with trypsin/EDTA.
Cells were washed with 0.9% NaCl containing 13 mM
D-glucose and resuspended in 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 13 mM
D-glucose, 20 mM HEPES buffer (pH 7.4) at
1-3 × 106 cells/ml. Cells were then incubated with
bis-(3-propyl-5-oxoisoxazol-4-yl)pentamethine oxonol (oxonol VI)
(Molecular Probes) (final concentration 2.5 µM) for 15 min at 37 °C. A cell suspension (2 ml) was placed in a stirred
quartz cuvette at 37 °C in a PerkinElmer Life Sciences LS50B
fluorimeter. After stabilization of the fluorescence signal (excitation
585 nm, slit 10 nm; emission, 645 nm, slit 5 nm), either an acidified
buffer control, acid-activated VacA (final concentration 5 µg/ml), or
non-activated VacA (5 µg/ml) was added to the cells. Further
depolarization was induced by addition of gramicidin A (20 µg/ml).
 |
RESULTS |
Analysis of the Role of GPI-anchored Proteins in VacA
Cytotoxicity--
A recent study reported that VacA cytotoxicity for
HEp-2 and HeLa cells was inhibited by treatment of the cells with
PI-PLC, an enzyme that cleaves GPI-anchored proteins from the cell
surface (31). Based on this result, it was proposed that the high
sensitivity of some cell types to VacA may be dependent on the presence
of intact GPI-anchored proteins. To investigate further whether VacA cytotoxic activity requires the presence of GPI-anchored proteins, we
analyzed the interactions of VacA with CHO-LA1 cells, which are
defective in production of GPI-anchored proteins. A previous study has
shown these cells are deficient in production of an enzyme encoded by
the PIG-L gene that is responsible for the
N-deacetylation of N-acetylglucosamine
phosphatidylinositol, which is the second step in GPI biosynthesis
(48). For comparison, we examined mutant CHO cells recomplemented with
the PIG-L gene (i.e. with restored capacity for production of GPI-anchored proteins) (48), hereafter designated as wild-type CHO cells. VacA was purified from the culture
supernatant of H. pylori 60190, and then both cell types were incubated for 18 h at 37 °C with varying concentrations of acid-activated VacA, ranging from 5 to 100 µg/ml. In agreement with
previous studies, the minimum concentration of VacA required to induce
vacuolation in >50% of CHO cells was about 10-fold higher than that
required to induce similar vacuolation of HeLa cells (31, 55, 56).
Importantly, wild-type CHO cells and CHO-LA1 mutant cells did not
differ substantially in susceptibility to VacA cytotoxicity (Fig.
1). As a control, we compared the
susceptibility of wild-type CHO cells and CHO-LA1 cells to the toxicity
of aerolysin (a bacterial pore-forming toxin that binds to GPI-anchored
proteins) (48, 57). As expected, wild-type CHO cells were highly
susceptible to the toxicity of aerolysin, whereas the mutant CHO cells
were resistant to aerolysin toxicity (Fig. 1). To examine possible internalization of VacA by wild-type CHO and CHO-LA1 cells, these cells
types were incubated with acid-activated VacA for 4 h at 37 °C,
and internalized toxin then was detected by indirect immunofluorescence and confocal microscopy. Acid-activated VacA was internalized to a
similar extent by wild-type CHO and CHO-LA1 mutant cells, and no
differences in the intracellular distribution of VacA were detectable
in these two cell types (Fig. 2). Thus,
in CHO cells, interaction of VacA with GPI-anchored proteins is not
required for either internalization of the toxin or vacuolating
cytotoxic effects.

View larger version (96K):
[in this window]
[in a new window]
|
Fig. 1.
Cytotoxic effects of aerolysin and VacA for
wild-type CHO cells and CHO-LA1 mutant cells. Wild-type CHO cells
and CHO-LA1 mutant cells were incubated with proaerolysin (150 ng/ml)
or with purified acid-activated VacA (25 µg/ml) in the presence of 5 mM ammonium chloride for 18 h at 37 °C. The cells
then were fixed with formaldehyde, stained with crystal violet, and
visualized by light microscopy. As expected, wild-type cells were
susceptible to aerolysin toxicity, whereas CHO-LA1 cells were
resistant. Both cell types were susceptible to the vacuolating
cytotoxic activity of VacA.
|
|

View larger version (66K):
[in this window]
[in a new window]
|
Fig. 2.
Internalization of VacA by wild-type CHO and
CHO-LA1 cells. Wild-type CHO cells and CHO-LA1 cells were
incubated with acid-activated VacA (1 µg/ml) for 4 h at
37 °C. The cells were fixed and permeabilized, and the localization
of VacA then was detected by indirect immunofluorescence microscopy
using a monoclonal anti-VacA antibody. VacA was localized in a punctate
pattern within the wild-type cells (A). The intracellular
localization of VacA in the mutant cells (B) was
indistinguishable from that in the wild-type CHO cells.
|
|
Interaction of VacA with Detergent-resistant Membrane
Microdomains--
Despite the lack of a requirement of GPI-anchored
proteins for VacA cytotoxicity or VacA internalization, we nevertheless investigated whether VacA was able to associate with lipid rafts and
whether such an association might be important for VacA cytotoxicity. Lipid rafts are membrane microdomains that are enriched in cholesterol, sphingolipids, and various membrane proteins, including GPI-anchored proteins. Notable characteristics of these membrane microdomains are
insolubility at 4 °C in the presence of certain non-ionic detergents
and a low buoyant density (36-39). To determine whether or not
H. pylori VacA interacts with detergent-resistant membranes (DRMs), HeLa cells were incubated with purified acid-activated VacA for
1 h at room temperature (25 °C). The cells then were lysed, and
Triton-insoluble cell components were separated by sucrose density
gradient centrifugation, as described under "Materials and
Methods." As expected, the transferrin receptor was detected almost
exclusively in fractions at the bottom of the gradient (Fig.
3A). In contrast, most of the
cell-associated VacA was found in low density fractions (Fig.
3B, lanes c and d). Similar results were obtained if VacA was incubated with HeLa cells at 4 °C instead of 25 °C, to prevent possible internalization of the toxin (data not
shown). The low density fractions that contained VacA were enriched in
alkaline phosphatase and CD55, two GPI-anchored proteins known to be
constituents of lipid rafts (Fig. 3D and data not shown).
When cell lysates were treated with the combination of 0.5% Triton
X-100 plus 0.5% saponin (instead of Triton X-100 alone) and then
analyzed by sucrose density gradient centrifugation, VacA was not
detected in low density fractions, but instead was detected
predominantly in fractions at the bottom of the gradient (Fig.
3C). Similarly, under these conditions alkaline phosphatase activity was not detected in low density fractions, but was detected exclusively in fractions at the bottom of the gradient (Fig.
3D). These results are consistent with the known capacity of
saponin to disrupt lipid rafts (51). As expected, when VacA was
analyzed directly on gradients (i.e. without first being
incubated with eukaryotic cells), all of the toxin was found at the
bottom of the gradient (data not shown). In parallel studies, we
analyzed interactions of VacA with DRMs of CHO cells and observed that acid-activated VacA associated with DRMs of both wild-type CHO cells
and CHO-LA1 mutant cells (Fig. 4). In
summary, these data show that VacA associates with DRMs of the plasma
membrane and indicate that GPI-anchored proteins are not required for
association of the toxin with DRMs.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 3.
Interaction of VacA with lipid rafts.
Acid-activated VacA from H. pylori 60190 was incubated with
HeLa cells for 1 h at room temperature (25 °C). Cells were
lysed with 1% Triton X-100, and insoluble cell components then were
separated by sucrose density gradient centrifugation. The gradient
fractions were analyzed by immunoblotting with either anti-transferrin
receptor antibodies (A) or anti-VacA serum (B).
The transferrin receptor was present in fractions at the bottom of the
gradient (A, lanes h and i), whereas
in contrast, a substantial proportion of the 88-kDa VacA band was
present in low density fractions (B, lanes c and
d). When VacA-treated cells were lysed in a mixture of 0.5%
Triton X-100 plus 0.5% saponin and insoluble cell components then were
analyzed, VacA was detected predominantly in fractions at the bottom of
the gradient (C). Alkaline phosphatase activity was detected
in low density fractions from cells treated with Triton X-100, but not
in low density fractions (lanes c and d) from
cells treated with the combination of saponin plus Triton X-100
(D).
|
|

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 4.
. Interaction of VacA with lipid rafts in
wild-type CHO cells and CHO-LA1 mutant cells. Acid-activated VacA
was incubated with wild-type CHO cells and with CHO-LA1 cells
(defective in production of GPI-anchored proteins) for 1.5 h at
25 °C. After lysing the cells, Triton-insoluble fractions were
analyzed by sucrose gradient centrifugation and immunoblotting of
fractions with anti-VacA serum. VacA was detected in low density
fractions prepared from both wild-type CHO cells (A) and
CHO-LA1 mutant cells (B).
|
|
Acid Activation of Purified VacA Increases Its Association with
DRMs--
Multiple previous studies (20-22) have shown that VacA
purified from H. pylori broth culture supernatants has very
little cytotoxic activity for cells unless the toxin is first exposed
to low pH or high pH conditions prior to contacting the cells (a
process known as "acid activation" or "alkaline activation").
Experiments using 125I-labeled VacA have shown that both
acid-activated and non-activated forms of the toxin can bind to HeLa
cells at 4 °C, but acid-activated VacA is internalized by cells to a
significantly greater extent than non-activated toxin (20). In
agreement with these results, analysis of the binding of the
non-labeled VacA to cells at 4 °C by immunoblotting confirmed that
both acid-activated and non-activated forms of the toxin can bind to
cells, although the acid-activated form bound to a somewhat greater
extent than the non-activated form (Fig.
5A). Confocal microscopy
studies indicated that when acid-activated VacA (1 µg/ml) was
incubated with HeLa cells for 4 h at 37 °C, it was internalized
and localized in a focal punctate distribution within the cells (Fig.
5B). In contrast, when non-activated VacA (1 µg/ml) was
incubated with cells under the same conditions, it was not detected in
such a distribution (Fig. 5C). When cells were incubated
with a 10-fold higher concentration of non-activated VacA (10 µg/ml),
a small proportion of cells demonstrated a detectable signal, but in
most cells VacA was again not detected in a focal punctate distribution
(data not shown).

View larger version (66K):
[in this window]
[in a new window]
|
Fig. 5.
. Acid activation of VacA enhances its
localization in lipid rafts. A, purified VacA was
either acid-activated or left untreated and then incubated with HeLa
cells at 4 °C for 1 h. Analysis of total cell lysates by
immunoblotting with anti-VacA serum indicated that both forms of the
toxin bound to cells and that the total binding of acid-activated VacA
to cells was greater than that of non-activated VacA. B and
C, HeLa cells were incubated with either acid-activated VacA
(1 µg/ml) or non-activated VacA (1 µg/ml) for 4 h at 37 °C.
The cells were fixed and permeabilized, and the localization of VacA
then was detected by indirect immunofluorescence microscopy, using
affinity-purified rabbit anti-VacA serum. Acid-activated VacA was
localized in a focal punctate pattern within the cells (B),
whereas this pattern of localization was not detected in cells treated
with non-activated VacA (C). D and E,
Triton-insoluble cell components were separated by sucrose density
gradient centrifugation, and gradient fractions were analyzed by
immunoblotting with anti-VacA serum. Acid-activated VacA was detected
in low density gradient fractions (D), whereas non-activated
VacA was detected predominantly in fractions at the bottom of the
gradient (E).
|
|
Based on this evidence that acid-activated VacA and non-activated VacA
interact differently with cells, we hypothesized that these two forms
of the toxin might interact differently with lipid rafts. To determine
whether interaction of VacA with lipid rafts requires activation of the
toxin, VacA was either acid-activated or left untreated and then added
directly to the neutral pH medium overlying HeLa cells. Cells were
incubated with VacA for 1 h at 25 °C. The association of VacA
with DRMs was then analyzed, as described above. Acid-activated VacA
was found in the low density gradient fractions corresponding to DRMs
(Fig. 5D), whereas non-activated VacA was found almost
exclusively at the bottom of the gradient (Fig. 5E). Similar
results were obtained if acid-activated VacA and non-activated VacA
were incubated with cells at 4 °C instead of room temperature (data
not shown). Thus, acid activation of the purified toxin resulted in a
marked increase in its association with DRMs. Because acid activation
markedly enhances the cytotoxic activity of purified VacA, the
foregoing observation suggested that VacA association with DRMs might
be an important feature of the intoxication process.
Inhibitory Effects of Methyl- -cyclodextrin on VacA
Cytotoxicity--
To investigate further the role of lipid rafts in
the process by which VacA intoxicates cells, we examined the effects of methyl- -cyclodextrin, an agent known to disrupt lipid rafts by extracting cholesterol from membranes (44). In preliminary experiments, we found that lipid rafts were more effectively disrupted by treatment of intact cells with high concentrations ( 10 mM) of
methyl- -cyclodextrin than by treatment with lower concentrations of
the drug, based on the distribution of alkaline phosphatase activity in
gradient fractions prepared from Triton-insoluble membranes. However,
treatment of intact HeLa cells with 10 mM
methyl- -cyclodextrin resulted in marked alterations in cell
morphology, whereas lower concentrations of methyl- -cyclodextrin
( 4 mM) did not. Therefore, subsequent experiments were
performed using a methyl- -cyclodextrin concentration of 4 mM. The total cholesterol content of cells treated with 4 mM methyl- -cyclodextrin at 37 °C for 30 min was 77 ± 2% of that in untreated cells.
HeLa cells were pretreated with 4 mM
methyl- -cyclodextrin in serum-free medium for 30 min and then were
incubated with acid-activated VacA. VacA induced marked vacuolation in
control (untreated) cells, but in contrast, no vacuoles were detected
when VacA was added to cells that had been pretreated with
methyl- -cyclodextrin (Fig. 6,
A-C). To test whether the observed inhibitory effects
resulted specifically from cholesterol depletion rather than from
direct inhibitory effects of methyl- -cyclodextrin, cells were
pretreated with 2 mM methyl- -cyclodextrin plus 2 mM methyl- -cyclodextrin-cholesterol complex, as
described by Thiele et al. (53), prior to addition of
acid-activated VacA. Thus, in this control experiment, the cells were
exposed to 4 mM methyl- -cyclodextrin, but there was no
depletion of cellular cholesterol content (data not shown). Under these
conditions, VacA induced prominent cell vacuolation (Fig.
6D). Additional control experiments were done in which
cholesterol was depleted by incubating cells with 4 mM
methyl- -cyclodextrin for 30 min, and then methyl- -cholesterol was
removed and cells were incubated with 5 mM
methyl- -cyclodextrin-cholesterol complex. Analysis of cellular
cholesterol content confirmed that this procedure effectively restored
cholesterol to its original levels. When added to cells manipulated as
described above, VacA induced prominent cell vacuolation (Fig.
6E). These experiments indicate that depletion of cellular
cholesterol renders cells resistant to the vacuolating activity of
VacA.

View larger version (71K):
[in this window]
[in a new window]
|
Fig. 6.
. Inhibitory effects of
methyl- -cyclodextrin on VacA-induced cell
vacuolation. HeLa cells were pretreated as described below,
incubated with acid-activated VacA (5 µg/ml) for 2 h at
37 °C, stained with crystal violet, and then visualized by
microscopy (magnification ×40). A, no pretreatment and no
addition of VacA. B, no pretreatment, followed by addition
of VacA. C, pretreatment with 4 mM
methyl- -cyclodextrin for 30 min prior to addition of VacA.
D, pretreatment with 2 mM
methyl- -cyclodextrin plus 2 mM
methyl- -cyclodextrin-cholesterol complex for 30 min prior to
addition of VacA. E, pretreatment with 4 mM
methyl- -cyclodextrin for 30 min, followed by removal of
methyl- -cyclodextrin and incubation with 5 mM
methyl- -cyclodextrin-cholesterol complex prior to addition of
VacA.
|
|
In parallel experiments, we analyzed the effects of
methyl- -cyclodextrin on the association of VacA with cells. In cells pretreated with methyl- -cyclodextrin, the total amount of
cell-associated VacA was detectably reduced compared with the amount of
cell-associated VacA in untreated cells (Fig.
7A). Next, DRMs were prepared
from VacA-treated cells that had been either pretreated or not
pretreated with methyl- -cyclodextrin. A reduction in alkaline
phosphatase activity in low density fractions indicated that DRMs were
partially disrupted by methyl- -cyclodextrin treatment (Fig.
7B). Also, the amount of VacA detected in low density
fractions was reduced, but not completely eliminated, by
methyl- -cyclodextrin treatment (Fig. 7C). These results
are consistent with the existence of heterogeneity among DRMs (58),
such that certain types of DRMs may be differentially affected by
cholesterol depletion.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 7.
. Effects of
methyl- -cyclodextrin on VacA interactions with
cells. A, HeLa cells were either pretreated with 4 mM methyl- -cyclodextrin or left untreated as a control
and then were incubated with acid-activated VacA for 4 h at
37 °C. Cells lysates then were analyzed by immunoblotting with
anti-VacA serum. B and C, HeLa cells were either
pretreated with 4 mM methyl- -cyclodextrin or left
untreated and then were incubated with acid-activated VacA for 1 h
at 25 °C. Triton-insoluble cell components were separated by sucrose
density centrifugation, and the alkaline phosphatase activity in
fractions was quantified (B). Gradient fractions were
analyzed for the presence of VacA by immunoblotting with anti-VacA
serum (C).
|
|
Additional experiments were done to investigate further the mechanism
by which methyl- -cyclodextrin inhibits VacA cytotoxicity. VacA is
known to form anion-selective channels in the plasma membrane of HeLa
cells, and the formation of these channels results in partial
depolarization of the resting membrane potential (24). To determine
whether methyl- -cyclodextrin pretreatment of cells inhibited the
capacity of VacA to induce depolarization of the plasma membrane, we
used bis-(3-propyl-5-oxoisoxazol-4-yl)pentamethine oxonol as a probe to
monitor the membrane potential of HeLa cells. Consistent with
previously published results (24), we found that following the addition
of acid-activated VacA, the resting membrane potential of HeLa cells
was rapidly altered (Fig. 8A). Following depolarization of the membrane by VacA, further
depolarization could be induced by addition of gramicidin A (20 µg/ml) (data not shown). Addition of non-activated VacA or an
acidified buffer control to the cells did not result in any detectable
alterations of the membrane potential (Fig. 8A and data not
shown). Interestingly, treatment with methyl- -cyclodextrin had no
effect on the membrane depolarization induced by acid-activated VacA
(Fig. 8A). These results indicate that treatment of the
cells with methyl- -cyclodextrin does not interfere with the capacity
of VacA to form channels in the plasma membrane.

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 8.
. Effects of
methyl- -cyclodextrin pretreatment on
VacA-induced alterations in membrane potential and VacA localization
within cells. A, HeLa cells were pretreated with 4 mM methyl- -cyclodextrin or left untreated and then were
loaded with oxonol VI (a probe used to monitor membrane potential).
Following addition of acid-activated VacA (5 µg/ml), the resting
membrane potential of both control (open square) and
cyclodextrin-treated cells (filled square) was rapidly
altered and reached a plateau within 2-3 min. Addition of
non-activated VacA (5 µg/ml) (filled circle) or acidified
buffer control (data not shown) did not induce any alteration in the
membrane potential. B, HeLa cells were pretreated as
described below and then incubated with acid-activated VacA for 4 h at 37 °C. The localization of VacA was assessed by indirect
immunofluorescence methodology and confocal microscopy, using a
monoclonal anti-VacA antibody. Top left panel, no
pretreatment and no addition of VacA. Top right panel, no
pretreatment, followed by addition of VacA. Bottom left
panel, pretreatment with 4 mM methyl- -cyclodextrin
for 30 min prior to addition of VacA. Bottom right panel,
pretreatment with 2 mM methyl- -cyclodextrin plus 2 mM methyl- -cyclodextrin-cholesterol complex for 30 min
prior to addition of VacA.
|
|
Since methyl- -cyclodextrin treatment inhibited VacA-induced
vacuolation but not channel formation by VacA at the plasma membrane, we hypothesized that internalization or trafficking of the toxin might
be altered in cholesterol-depleted cells. We therefore assessed the
localization of VacA in methyl- -cyclodextrin-treated cells. Whereas
VacA was detected in an intracellular focal punctate distribution in
untreated cells, only a diffuse distribution could be seen in
cyclodextrin-treated cells (Fig. 8B), even when using a
10-fold higher concentration of acid-activated VacA (data not shown). To determine whether the altered distribution of VacA resulted from
cholesterol depletion or from direct effects of the
methyl- -cyclodextrin, control experiments were performed in which
cells were incubated with the same dose of cyclodextrin in the presence
of excess cholesterol. Under these conditions, VacA localized in an
intracellular focal punctate distribution (Fig. 8B).
Similarly, if cellular cholesterol was depleted and subsequently
replaced, VacA localized in the same intracellular focal punctate
distribution (data not shown). These results indicate that cholesterol
depletion induced by methyl- -cyclodextrin disrupts the cellular
processes normally utilized for internalization or intracellular
trafficking of VacA.
In agreement with a previous report (31), we found that treatment of
cells with nystatin also inhibited VacA-induced vacuolation (Fig.
9A). Nystatin binds to
cholesterol but does not deplete cellular cholesterol levels, and
therefore, as expected, the cholesterol content of nystatin-treated
cells was not different compared with that of untreated cells.
Treatment of cells with nystatin produced fairly modest effects on raft
integrity and VacA association with rafts (data not shown), similar to
the results observed following treatment with 4 mM
methyl- -cyclodextrin (Fig. 7). However, treatment of cells with
nystatin interfered with the internalization or intracellular
localization of VacA (Fig. 9B). Thus, binding of nystatin to
cellular cholesterol produced essentially the same effects on VacA
activity and localization as those that were observed following
depletion of cellular cholesterol.

View larger version (114K):
[in this window]
[in a new window]
|
Fig. 9.
. Inhibitory effects of nystatin on
VacA-induced cell vacuolation. HeLa cells were either pretreated
with nystatin (40 µg/ml) for 1 h at 37 °C or not pretreated
and then incubated with acid-activated VacA (5 µg/ml) at 37 °C.
A, cells were fixed and stained with crystal violet.
Addition of VacA induced vacuolation in untreated cells (left
panel), but not in cells pretreated with nystatin (right
panel). B, the localization of VacA was assessed by
indirect immunofluorescence methodology and confocal microscopy, using
a monoclonal anti-VacA antibody. VacA was localized in a focal punctate
intracellular distribution in untreated cells (left panel),
but not in cells that had been pretreated with nystatin (right
panel).
|
|
 |
DISCUSSION |
Binding of bacterial protein toxins to eukaryotic cells often is
mediated by an interaction of the toxin with a specific receptor on the
cell surface. Several previous studies have provided evidence for
saturability and specificity of VacA binding to cells (59-61). In
contrast, studies with radiolabeled VacA have not demonstrated convincing evidence of a saturable binding process, and the binding of
radiolabeled VacA was only partially inhibited by excess unlabeled VacA
(20, 31). At least five different putative receptors for VacA have been
reported, including receptor protein tyrosine phosphatase , an
unidentified 140-kDa protein, the epidermal growth factor receptor,
heparan sulfate, and various lipids (22, 23, 62-65). It has also been
reported that that treatment of cells with either nystatin or PI-PLC
inhibits VacA cytotoxicity, and based on this observation, it was
proposed that intact lipid rafts and GPI-anchored proteins are required
for VacA susceptibility (31). Thus, at present, there is considerable
confusion about which cell surface components are most relevant for
VacA binding and cytotoxicity. It remains unclear whether VacA
cytotoxicity is dependent on binding of VacA to one specific receptor
or whether cytotoxicity results from nonspecific binding of VacA to
multiple cell-surface components.
Several different bacterial protein toxins seem to utilize lipid rafts
or raft-associated GPI-anchored proteins to intoxicate cells. Two
pore-forming toxins, aerolysin and Clostridium septicum alpha toxin, each bind to GPI-anchored proteins, which are enriched in
lipid raft microdomains of the plasma membrane (57, 66). Other
pore-forming toxins, such as perfringolysin, bind to cholesterol components of lipid rafts (43). It has been proposed that lipid rafts
serve as concentrating platforms to promote oligomerization of these
toxins on the cell surface, a process that is required for membrane
channel formation (57). Two toxins with intracellular enzymatic
activity, cholera toxin and tetanus toxin, bind to GM1 and a specific
GPI-anchored protein, respectively, which are enriched in lipid raft
microdomains (43-45, 58, 67). It has been proposed that lipid
rafts play an important role in the internalization and intracellular
trafficking of these toxins (44, 58, 67). The conclusion that these
bacterial protein toxins require lipid rafts for intoxication of cells
has been based mainly on experiments that utilize cyclodextrin or other
cholesterol-interacting drugs to alter lipid rafts.
In the current study, we provide direct biochemical evidence indicating
that VacA associates with lipid rafts. Moreover, we find that VacA is
still able to associate with lipid rafts, undergo internalization, and
induce cytotoxic effects in the absence of GPI-anchored proteins.
Although our conclusions about VacA interactions with GPI-anchored
proteins in CHO cells are unequivocal, these data do not completely
exclude the possibility that GPI-anchored proteins might contribute to
the high sensitivity of various other cell types to VacA cytotoxicity.
Notably, a previous report found that doses of PI-PLC sufficient to
block VacA activity in HEp-2 cells had no significant effect on
125I-VacA binding to these cells (31). This result is
consistent with the concept that there may be multiple binding sites
and/or multiple internalization pathways by which VacA intoxicates
cells (31). We speculate that the inhibitory effect seen with PI-PLC could be due to changes in raft properties that occur when GPI-anchored proteins are acutely removed by the enzymatic treatment. In contrast, GPI-deficient cells grow continuously in the absence of GPI-anchored proteins and therefore are perhaps able to compensate for this defect.
In agreement with a previous report (31), we found in the current study
that treatment of cells with nystatin inhibits the activity of VacA.
Our demonstration that acid-activated (active) forms of VacA associate
with lipid rafts, whereas non-activated (inactive) forms do not,
provides further evidence suggesting that interaction of VacA with
lipid rafts is required for cytotoxicity. Finally, we found that
treatment of cells with methyl- -cyclodextrin, a
cholesterol-depleting agent known to disrupt rafts, inhibits VacA
cytotoxicity. Interestingly, the doses of cholesterol-interacting drugs
used in this study resulted in nearly complete inhibition of
VacA-induced cell vacuolation, but only partially disrupted DRMs and
incompletely inhibited VacA association with DRMs. Moreover, methyl- -cyclodextrin did not inhibit the capacity of VacA to depolarize the plasma membrane of cells. However, treatment of cells
with cholesterol-interacting drugs strongly interfered with either the
internalization or intracellular localization of VacA. Thus, it seems
likely that early events (e.g. binding of the toxin to
cells) in the VacA intoxication process are not substantially affected
by these compounds but that their inhibitory effects are mainly due to
interference with later events (e.g. internalization and
intracellular trafficking of VacA). This interpretation is consistent
with the concept that raft-dependent mechanisms are important for intracellular sorting events (68-71). We
speculate that there is heterogeneity among DRMs (58) and that
functional properties of certain types of DRMs relevant for
intracellular trafficking processes may be especially susceptible to
disruption by drugs such as methyl- -cyclodextrin and nystatin. In
future studies, it will be important to investigate further the role of
lipid rafts and cellular cholesterol content on the intracellular trafficking of various bacterial protein toxins, viruses, and bacterial pathogens.
 |
ACKNOWLEDGEMENT |
We thank Beverly Hosse for assistance with
VacA purification.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grants DK53623 and AI39657 and by the Medical Research Service of the Department of Veterans Affairs.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
These authors contributed equally to this work.

To whom correspondence should be addressed: Division of
Infectious Diseases, A3310 MCN, Vanderbilt University School of
Medicine, Nashville, TN 37232. Tel.: 615-322-2035; Fax: 615-343-6160;
E-mail: COVERTL@ctrvax.vanderbilt.edu.
Published, JBC Papers in Press, July 16, 2002, DOI 10.1074/jbc.M203466200
 |
ABBREVIATIONS |
The abbreviations used are:
GPI, glycosylphosphatidylinositol;
PI-PLC, phosphatidylinositol-specific
phospholipase C;
CHO, Chinese hamster ovary;
TBS, Tris-buffered saline;
PBS, phosphate-buffered saline;
BSA, bovine serum albumin;
DRM, detergent-resistant membrane.
 |
REFERENCES |
| 1.
|
Cover, T. L.,
Berg, D. E.,
Blaser, M. J.,
and Mobley, H. L. T.
(2001)
in
Principles of Bacterial Pathogenesis
(Groisman, E. A., ed)
, pp. 510-558, Academic Press, San Diego, CA
|
| 2.
|
Dunn, B. E.,
Cohen, H.,
and Blaser, M. J.
(1997)
Clin. Microbiol. Rev.
10,
720-741[Abstract]
|
| 3.
|
Atherton, J. C.,
Cover, T. L.,
Papini, E.,
and Telford, J. L.
(2001)
in
Helicobacter pylori: Physiology and Genetics
(Mobley, H. L. T.
, Mendz, G. L.
, and Hazell, S. L., eds)
, pp. 97-110, ASM Press, Washington, D. C.
|
| 4.
|
Montecucco, C.,
Papini, E.,
de Bernard, M.,
Telford, J. L.,
and Rappuoli, R.
(1999)
in
The Comprehensive Sourcebook of Bacterial Protein Toxins
(Alouf, J. E.
, and Freer, J. H., eds)
, pp. 264-286, Academic Press, San Diego, CA
|
| 5.
|
Papini, E.,
Zoratti, M.,
and Cover, T. L.
(2001)
Toxicon
39,
1757-1767[Medline]
[Order article via Infotrieve]
|
| 6.
|
Salama, N. R.,
Otto, G.,
Tompkins, L.,
and Falkow, S.
(2001)
Infect. Immun.
69,
730-736[Abstract/Free Full Text]
|
| 7.
|
Telford, J. L.,
Ghiara, P.,
Dell'Orco, M.,
Comanducci, M.,
Burroni, D.,
Bugnoli, M.,
Tecce, M. F.,
Censini, S.,
Covacci, A.,
Xiang, Z.,
Papini, E.,
Montecucco, C.,
Parente, L.,
and Rappuoli, R.
(1994)
J. Exp. Med.
179,
1653-1658[Abstract/Free Full Text]
|
| 8.
|
Ogura, K.,
Maeda, S.,
Nakao, M.,
Watanabe, T.,
Tada, M.,
Kyutoku, T.,
Yoshida, H.,
Shiratori, Y.,
and Omata, M.
(2000)
J. Exp. Med.
192,
1601-1610[Abstract/Free Full Text]
|
| 9.
|
Atherton, J. C.,
Cao, P.,
Peek, R. M., Jr.,
Tummuru, M. K.,
Blaser, M. J.,
and Cover, T. L.
(1995)
J. Biol. Chem.
270,
17771-17777[Abstract/Free Full Text]
|
| 10.
|
Gerhard, M.,
Lehn, N.,
Neumayer, N.,
Boren, T.,
Rad, R.,
Schepp, W.,
Miehlke, S.,
Classen, M.,
and Prinz, C.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
12778-12783[Abstract/Free Full Text]
|
| 11.
|
Van Doorn, L. J.,
Figueiredo, C.,
Megraud, F.,
Pena, S.,
Midolo, P.,
Queiroz, D. M.,
Carneiro, F.,
Vanderborght, B.,
Pegado, M. D.,
Sanna, R., De,
Boer, W.,
Schneeberger, P. M.,
Correa, P., Ng, E. K.,
Atherton, J.,
Blaser, M. J.,
and Quint, W. G.
(1999)
Gastroenterology
116,
823-830[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
van Doorn, L. J.,
Figueiredo, C.,
Sanna, R.,
Plaisier, A.,
Schneeberger, P.,
de Boer, W.,
and Quint, W.
(1998)
Gastroenterology
115,
58-66[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
De Gusmao, V. R.,
Nogueira Mendes, E., De,
Magalhaes Queiroz, D. M.,
Aguiar Rocha, G.,
Camargos Rocha, A. M.,
Ramadan Ashour, A. A.,
and Teles Carvalho, A. S.
(2000)
J. Clin. Microbiol.
38,
2853-2857[Abstract/Free Full Text]
|
| 14.
|
Han, S. R.,
Schreiber, H. J.,
Bhakdi, S.,
Loos, M.,
and Maeurer, M. J.
(1998)
Clin. Diagn. Lab. Immunol.
5,
139-145[Medline]
[Order article via Infotrieve]
|
| 15.
|
Nguyen, V. Q.,
Caprioli, R. M.,
and Cover, T. L.
(2001)
Infect. Immun.
69,
543-546[Abstract/Free Full Text]
|
| 16.
|
Fischer, W.,
Buhrdorf, R.,
Gerland, E.,
and Haas, R.
(2001)
Infect. Immun.
69,
6769-6775[Abstract/Free Full Text]
|
| 17.
|
Adrian, M.,
Cover, T. L.,
Dubochet, J.,
and Heuser, J. E.
(2002)
J. Mol. Biol.
318,
121-133[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Cover, T. L.,
Hanson, P. I.,
and Heuser, J. E.
(1997)
J. Cell Biol.
138,
759-769[Abstract/Free Full Text]
|
| 19.
|
Lupetti, P.,
Heuser, J. E.,
Manetti, R.,
Massari, P.,
Lanzavecchia, S.,
Bellon, P. L.,
Dallai, R.,
Rappuoli, R.,
and Telford, J. L.
(1996)
J. Cell Biol.
133,
801-807[Abstract/Free Full Text]
|
| 20.
|
McClain, M. S.,
Schraw, W.,
Ricci, V.,
Boquet, P.,
and Cover, T. L.
(2000)
Mol. Microbiol.
37,
433-442[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
de Bernard, M.,
Papini, E.,
de Filippis, V.,
Gottardi, E.,
Telford, J.,
Manetti, R.,
Fontana, A.,
Rappuoli, R.,
and Montecucco, C.
(1995)
J. Biol. Chem.
270,
23937-23940[Abstract/Free Full Text]
|
| 22.
|
Yahiro, K.,
Niidome, T.,
Kimura, M.,
Hatakeyama, T.,
Aoyagi, H.,
Kurazono, H.,
Imagawa, K.,
Wada, A.,
Moss, J.,
and Hirayama, T.
(1999)
J. Biol. Chem.
274,
36693-36699[Abstract/Free Full Text]
|
| 23.
|
Czajkowsky, D. M.,
Iwamoto, H.,
Cover, T. L.,
and Shao, Z.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2001-2006[Abstract/Free Full Text]
|
| 24.
|
Szabo, I.,
Brutsche, S.,
Tombola, F.,
Moschioni, M.,
Satin, B.,
Telford, J. L.,
Rappuoli, R.,
Montecucco, C.,
Papini, E.,
and Zoratti, M.
(1999)
EMBO J.
18,
5517-5527[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Tombola, F.,
Carlesso, C.,
Szabo, I.,
de Bernard, M.,
Reyrat, J. M.,
Telford, J. L.,
Rappuoli, R.,
Montecucco, C.,
Papini, E.,
and Zoratti, M.
(1999)
Biophys. J.
76,
1401-1409[Medline]
[Order article via Infotrieve]
|
| 26.
|
Iwamoto, H.,
Czajkowsky, D. M.,
Cover, T. L.,
Szabo, G.,
and Shao, Z.
(1999)
FEBS Lett.
450,
101-104[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Garner, J. A.,
and Cover, T. L.
(1996)
Infect. Immun.
64,
4197-4203[Abstract]
|
| 28.
|
Ricci, V.,
Sommi, P.,
Fiocca, R.,
Romano, M.,
Solcia, E.,
and Ventura, U.
(1997)
J. Pathol.
183,
453-459[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
de Bernard, M.,
Arico, B.,
Papini, E.,
Rizzuto, R.,
Grandi, G.,
Rappuoli, R.,
and Montecucco, C.
(1997)
Mol. Microbiol.
26,
665-674[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Ye, D.,
Willhite, D. C.,
and Blanke, S. R.
(1999)
J. Biol. Chem.
274,
9277-9282[Abstract/Free Full Text]
|
| 31.
|
Ricci, V.,
Galmiche, A.,
Doye, A.,
Necchi, V.,
Solcia, E.,
and Boquet, P.
(2000)
Mol. Biol. Cell
11,
3897-3909[Abstract/Free Full Text]
|
| 32.
|
Galmiche, A.,
Rassow, J.,
Doye, A.,
Cagnol, S.,
Chambard, J. C.,
Contamin, S.,
de Thillot, V.,
Just, I.,
Ricci, V.,
Solcia, E.,
Van Obberghen, E.,
and Boquet, P.
(2000)
EMBO J.
19,
6361-6370[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Ye, D.,
and Blanke, S. R.
(2002)
Mol. Microbiol.
43,
1243-1253[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
McClain, M. S.,
Cao, P.,
Iwamoto, H.,
Vinion-Dubiel, A. D.,
Szabo, G.,
Shao, Z.,
and Cover, T. L.
(2001)
J. Bacteriol.
183,
6499-6508[Abstract/Free Full Text]
|
| 35.
|
Fivaz, M.,
Abrami, L.,
and van der Goot, F. G.
(1999)
Trends Cell Biol.
9,
212-213[Medline]
[Order article via Infotrieve]
|
| 36.
|
Friedrichson, T.,
and Kurzchalia, T. V.
(1998)
Nature
394,
802-805[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Simons, K.,
and Ikonen, E.
(1997)
Nature
387,
569-572[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Brown, D. A.,
and London, E.
(1998)
Annu. Rev. Cell Dev. Biol.
14,
111-136[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Harder, T.,
and Simons, K.
(1997)
Curr. Opin. Cell Biol.
9,
534-542[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Nichols, B. J.,
and Lippincott-Schwartz, J.
(2001)
Trends Cell Biol.
11,
406-412[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
van der Goot, F. G.,
and Harder, T.
(2001)
Semin. Immunol.
13,
89-97[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Zitzer, A.,
Zitzer, O.,
Bhakdi, S.,
and Palmer, M.
(1999)
J. Biol. Chem.
274,
1375-1380[Abstract/Free Full Text]
|
| 43.
|
Waheed, A. A.,
Shimada, Y.,
Heijnen, H. F. G.,
Nakamura, M.,
Inomata, M.,
Hayashi, M.,
Iwashita, S.,
Slot, J. W.,
and Ohno-Iwashita, Y.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
4926-4931[Abstract/Free Full Text]
|
| 44.
|
Orlandi, P. A.,
and Fishman, P. H.
(1998)
J. Cell Biol.
141,
905-915[Abstract/Free Full Text]
|
| 45.
|
Wolf, A. A.,
Jobling, M. G.,
Wimer-Mackin, S.,
Ferguson-Maltzman, M.,
Madara, J. L.,
Holmes, R. K.,
and Lencer, W. I.
(1998)
J. Cell Biol.
141,
917-927[Abstract/Free Full Text]
|
| 46.
|
Abrami, L.,
and van Der Goot, F. G.
(1999)
J. Cell Biol.
147,
175-184[Abstract/Free Full Text]
|
| 47.
|
Buckley, J. T.
(1990)
Biochem. Cell Biol.
68,
221-224[Medline]
[Order article via Infotrieve]
|
| 48.
|
Abrami, L.,
Fivaz, M.,
Kobayashi, T.,
Kinoshita, T.,
Parton, R. G.,
and van der Goot, F. G.
(2001)
J. Biol. Chem.
276,
30729-30736[Abstract/Free Full Text]
|
| 49.
|
Cover, T. L.,
Vaughn, S. G.,
Cao, P.,
and Blaser, M. J.
(1992)
J. Infect. Dis.
166,
1073-1078[Medline]
[Order article via Infotrieve]
|
| 50.
|
Cover, T. L.,
Puryear, W.,
Pérez-Pérez, G. I.,
and Blaser, M. J.
(1991)
Infect. Immun.
59,
1264-1270[Abstract/Free Full Text]
|
| 51.
|
Chamberlain, L. H.,
Burgoyne, R. D.,
and Gould, G. W.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
5619-5624[Abstract/Free Full Text]
|
| 52.
|
Vinion-Dubiel, A. D.,
McClain, M. S.,
Cao, P.,
Mernaugh, R. L.,
and Cover, T. L.
(2001)
Infect. Immun.
69,
4329-4336[Abstract/Free Full Text]
|
| 53.
|
Thiele, C.,
Hannah, M. J.,
Fahrenholz, F.,
and Huttner, W. B.
(2000)
Nat. Cell Biol.
2,
42-49[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Klein, U.,
Gimpl, G.,
and Fahrenholz, F.
(1995)
Biochemistry
34,
13784-13793[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Leunk, R. D.,
Johnson, P. T.,
David, B. C.,
Kraft, W. G.,
and Morgan, D. R.
(1988)
J. Med. Microbiol.
26,
93-99[Abstract/Free Full Text]
|
| 56.
|
Smoot, D. T.,
Resau, J. H.,
Earlington, M. H.,
Simpson, M.,
and Cover, T. L.
(1996)
Gut
39,
795-799[Abstract/Free Full Text]
|
| 57.
|
Abrami, L.,
Fivaz, M.,
Glauser, P. E.,
Parton, R. G.,
and van der Goot, F. G.
(1998)
J. Cell Biol.
140,
525-540[Abstract/Free Full Text]
|
| 58.
|
Herreros, J., Ng, T.,
and Schiavo, G.
(2001)
Mol. Biol. Cell
12,
2947-2960[Abstract/Free Full Text]
|
| 59.
|
Wang, W.-C.,
Wang, H.-J.,
and Kuo, C.-H.
(2001)
Biochemistry
40,
11887-11896[CrossRef][Medline]
[Order article via Infotrieve]
|
| 60.
|
Massari, P.,
Manetti, R.,
Burroni, D.,
Nuti, S.,
Norais, N.,
Rappuoli, R.,
and Telford, J. L.
(1998)
Infect. Immun.
66,
3981-3984[Abstract/Free Full Text]
|
| 61.
|
Pagliaccia, C.,
de Bernard, M.,
Lupetti, P., Ji, X.,
Burroni, D.,
Cover, T. L.,
Papini, E.,
Rappuoli, R.,
Telford, J. L.,
and Reyrat, J. M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
10212-10217[Abstract/Free Full Text]
|
| 62.
|
Yahiro, K.,
Niidome, T.,
Hatakeyama, T.,
Aoyagi, H.,
Kurazono, H.,
Padilla, P. I.,
Wada, A.,
and Hirayama, T.
(1997)
Biochem. Biophys. Res. Commun.
238,
629-632[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Seto, K.,
Hayashi-Kuwabara, Y.,
Yoneta, T.,
Suda, H.,
and Tamaki, H.
(1998)
FEBS Lett.
431,
347-350[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Moll, G.,
Papini, E.,
Colonna, R.,
Burroni, D.,
Telford, J.,
Rappuoli, R.,
and Montecucco, C.
(1995)
Eur. J. Biochem.
234,
947-952[Medline]
[Order article via Infotrieve]
|
| 65.
|
Molinari, M.,
Galli, C.,
de Bernard, M.,
Norais, N.,
Ruysschaert, J. M.,
Rappuoli, R.,
and Montecucco, C.
(1998)
Biochem. Biophys. Res. Commun.
248,
334-340[CrossRef][Medline]
[Order article via Infotrieve]
|
| 66.
|
Gordon, V. M.,
Nelson, K. L.,
Buckley, J. T.,
Stevens, V. L.,
Tweten, R. K.,
Elwood, P. C.,
and Leppla, S. H.
(1999)
J. Biol. Chem.
274,
27274-27280[Abstract/Free Full Text]
|
| 67.
|
Lencer, W. I.
(2001)
Am. J. Physiol.
280,
G781-G786
|
| 68.
|
Grimmer, S.,
Iversen, T. G.,
van Deurs, B.,
and Sandvig, K.
(2000)
Mol. Biol. Cell
11,
4205-4216[Abstract/Free Full Text]
|
| 69.
|
Hoekstra, D.,
and van Ijzendoorn, S. C. D.
(2000)
Curr. Opin. Cell Biol.
12,
496-502[CrossRef][Medline]
[Order article via Infotrieve]
|
| 70.
|
Mukherjee, S.,
and Maxfield, F. R.
(2000)
Traffic
1,
203-211[CrossRef][Medline]
[Order article via Infotrieve]
|
| 71.
|
Simons, K.,
and Toomre, D.
(2000)
Nat. Rev. Mol. Cell. Biol.
1,
31-39[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Kobayashi, H. Lee, J. Nakayama, and M. Fukuda
Roles of gastric mucin-type O-glycans in the pathogenesis of Helicobacter pylori infection
Glycobiology,
May 1, 2009;
19(5):
453 - 461.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Wang, P. Xia, F. Wu, D. Wang, W. Wang, T. Ward, Y. Liu, F. Aikhionbare, Z. Guo, M. Powell, et al.
Helicobacter pylori VacA Disrupts Apical Membrane-Cytoskeletal Interactions in Gastric Parietal Cells
J. Biol. Chem.,
September 26, 2008;
283(39):
26714 - 26725.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E. Ivie, M. S. McClain, V. J. Torres, H. M. S. Algood, D. B. Lacy, R. Yang, S. R. Blanke, and T. L. Cover
Helicobacter pylori VacA Subdomain Required for Intracellular Toxin Activity and Assembly of Functional Oligomeric Complexes
Infect. Immun.,
July 1, 2008;
76(7):
2843 - 2851.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-H. Lai, Y.-C. Chang, S.-Y. Du, H.-J. Wang, C.-H. Kuo, S.-H. Fang, H.-W. Fu, H.-H. Lin, A.-S. Chiang, and W.-C. Wang
Cholesterol Depletion Reduces Helicobacter pylori CagA Translocation and CagA-Induced Responses in AGS Cells
Infect. Immun.,
July 1, 2008;
76(7):
3293 - 3303.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Burgermeister, X. Xing, C. Rocken, M. Juhasz, J. Chen, M. Hiber, K. Mair, M. Shatz, M. Liscovitch, R. M. Schmid, et al.
Differential Expression and Function of Caveolin-1 in Human Gastric Cancer Progression
Cancer Res.,
September 15, 2007;
67(18):
8519 - 8526.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. C. Gauthier, P. Monzo, T. Gonzalez, A. Doye, A. Oldani, P. Gounon, V. Ricci, M. Cormont, and P. Boquet
Early endosomes associated with dynamic F-actin structures are required for late trafficking of H. pylori VacA toxin
J. Cell Biol.,
April 23, 2007;
177(2):
343 - 354.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Nakayama, J. Hisatsune, E. Yamasaki, Y. Nishi, A. Wada, H. Kurazono, J. Sap, K. Yahiro, J. Moss, and T. Hirayama
Clustering of Helicobacter pylori VacA in Lipid Rafts, Mediated by Its Receptor, Receptor-Like Protein Tyrosine Phosphatase {beta}, Is Required for Intoxication in AZ-521 Cells
Infect. Immun.,
December 1, 2006;
74(12):
6571 - 6580.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. McClain, D. M. Czajkowsky, V. J. Torres, G. Szabo, Z. Shao, and T. L. Cover
Random Mutagenesis of Helicobacter pylori vacA To Identify Amino Acids Essential for Vacuolating Cytotoxic Activity
Infect. Immun.,
November 1, 2006;
74(11):
6188 - 6195.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. J. Torres, M. S. McClain, and T. L. Cover
Mapping of a Domain Required for Protein-Protein Interactions and Inhibitory Activity of a Helicobacter pylori Dominant-Negative VacA Mutant Protein
Infect. Immun.,
April 1, 2006;
74(4):
2093 - 2101.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Jandu, P. J. M. Ceponis, S. Kato, J. D. Riff, D. M. McKay, and P. M. Sherman
Conditioned Medium from Enterohemorrhagic Escherichia coli-Infected T84 Cells Inhibits Signal Transducer and Activator of Transcription 1 Activation by Gamma Interferon
Infect. Immun.,
March 1, 2006;
74(3):
1809 - 1818.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. C. Gauthier, P. Monzo, V. Kaddai, A. Doye, V. Ricci, and P. Boquet
Helicobacter pylori VacA Cytotoxin: A Probe for a Clathrin-independent and Cdc42-dependent Pinocytic Pathway Routed to Late Endosomes
Mol. Biol. Cell,
October 1, 2005;
16(10):
4852 - 4866.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Fitchen, D. P Letley, P. O'Shea, J. C Atherton, P. Williams, and K. R Hardie
All subtypes of the cytotoxin VacA adsorb to the surface of Helicobacter pylori post-secretion
J. Med. Microbiol.,
July 1, 2005;
54(7):
621 - 630.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. J. Torres, S. E. Ivie, M. S. McClain, and T. L. Cover
Functional Properties of the p33 and p55 Domains of the Helicobacter pylori Vacuolating Cytotoxin
J. Biol. Chem.,
June 3, 2005;
280(22):
21107 - 21114.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. R. Henderson, F. Navarro-Garcia, M. Desvaux, R. C. Fernandez, and D. Ala'Aldeen
Type V Protein Secretion Pathway: the Autotransporter Story
Microbiol. Mol. Biol. Rev.,
December 1, 2004;
68(4):
692 - 744.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Wada, E. Yamasaki, and T. Hirayama
Helicobacter pylori Vacuolating Cytotoxin, VacA, Is Responsible for Gastric Ulceration
J. Biochem.,
December 1, 2004;
136(6):
741 - 746.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Nagahama, A. Yamaguchi, T. Hagiyama, N. Ohkubo, K. Kobayashi, and J. Sakurai
Binding and Internalization of Clostridium perfringens Iota-Toxin in Lipid Rafts
Infect. Immun.,
June 1, 2004;
72(6):
3267 - 3275.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kim, A. K. Chamberlain, and J. U. Bowie
Membrane channel structure of Helicobacter pylori vacuolating toxin: Role of multiple GXXXG motifs in cylindrical channels
PNAS,
April 20, 2004;
101(16):
5988 - 5991.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Li, A. Wandinger-Ness, J. R. Goldenring, and T. L. Cover
Clustering and Redistribution of Late Endocytic Compartments in Response to Helicobacter pylori Vacuolating Toxin
Mol. Biol. Cell,
April 1, 2004;
15(4):
1946 - 1959.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. C. Gauthier, V. Ricci, P. Gounon, A. Doye, M. Tauc, P. Poujeol, and P. Boquet
Glycosylphosphatidylinositol-anchored Proteins and Actin Cytoskeleton Modulate Chloride Transport by Channels Formed by the Helicobacter pylori Vacuolating Cytotoxin VacA in HeLa Cells
J. Biol. Chem.,
March 5, 2004;
279(10):
9481 - 9489.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. J. Torres, M. S. McClain, and T. L. Cover
Interactions between p-33 and p-55 Domains of the Helicobacter pylori Vacuolating Cytotoxin (VacA)
J. Biol. Chem.,
January 16, 2004;
279(3):
2324 - 2331.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Boncristiano, S. R. Paccani, S. Barone, C. Ulivieri, L. Patrussi, D. Ilver, A. Amedei, M. M. D'Elios, J. L. Telford, and C. T. Baldari
The Helicobacter pylori Vacuolating Toxin Inhibits T Cell Activation by Two Independent Mechanisms
J. Exp. Med.,
December 15, 2003;
198(12):
1887 - 1897.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Latif, T. Ando, S. Daniel, and T. F. Davies
Localization and Regulation of Thyrotropin Receptors within Lipid Rafts
Endocrinology,
November 1, 2003;
144(11):
4725 - 4728.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Nagahama, S. Hayashi, S. Morimitsu, and J. Sakurai
Biological Activities and Pore Formation of Clostridium perfringens Beta Toxin in HL 60 Cells
J. Biol. Chem.,
September 19, 2003;
278(38):
36934 - 36941.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. McClain, H. Iwamoto, P. Cao, A. D. Vinion-Dubiel, Y. Li, G. Szabo, Z. Shao, and T. L. Cover
Essential Role of a GXXXG Motif for Membrane Channel Formation by Helicobacter pylori Vacuolating Toxin
J. Biol. Chem.,
March 28, 2003;
278(14):
12101 - 12108.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Guillemin, N. R. Salama, L. S. Tompkins, and S. Falkow
Cag pathogenicity island-specific responses of gastric epithelial cells to Helicobacter pylori infection
PNAS,
November 12, 2002;
99(23):
15136 - 15141.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|